Genetic Influences on Pharmacological Interventions in PsoriasisHana Ahmad1 and Nabiha Yusuf2*
- *Corresponding Author:
- Nabiha Yusuf
Department of Dermatology
University of Alabama at Birmingham
1670 University Boulevard, VH 566A
PO Box 202, Birmingham, Alabama , USA
Tel: 205 934-7432
E-mail: [email protected]
Received Date: April 14, 2017; Accepted Date: April 20, 2017; Published Date: April 24, 2017
Citation: Ahmad H, Yusuf N (2017) Genetic Influences on Pharmacological Interventions in Psoriasis. J Clin Exp Dermatol Res 8:392. doi: 10.4172/2155-9554.1000392
Copyright: © Ahmad H, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Psoriasis is a common chronic inflammatory disease that affects 2% of the population. Therapeutic intervention for psoriasis mainly targets inflammatory cascade through the use of topical agents, phototherapy, systemic agents and the newer biologic agents. The efficacy of many treatments used in psoriasis varies from patient to patient, and some of this variance in response can presumably be attributed to genetic differences. While current research findings are still limited, the clinical utilization of pharmacogenetics allows for tailored treatment plans that have the potential for better response amongst patients as well as conserving expenditures and healthcare resources. In this review, we hope to focus and summarize the conclusions and findings of studies done on the topic of pharmacogenetics in the treatment of psoriasis.